MIM
AXSM icon

MetLife Investment Management’s Axsome Therapeutics AXSM Stock Holding History

MetLife Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
89,662
-62,983
-41% -$13.7M 0.1% 159
2026
Q1 		$25.8M Sell
152,645
-12,226
-7% -$2.11M 0.13% 118
2025
Q4 		$30.1M Sell
164,871
-32,447
-16% -$4.53M 0.15% 98
2025
Q3 		$24M Buy
197,318
+13,154
+7% +$1.48M 0.12% 130
2025
Q2 		$19.2M Buy
184,164
+5,209
+3% +$552K 0.11% 158
2025
Q1 		$20.9M Buy
178,955
+156,678
+703% +$17.8M 0.11% 146
2024
Q4 		$1.88M Buy
22,277
+1,232
+6% +$113K 0.01% 1075
2024
Q3 		$1.89M Hold
21,045
– – 0.01% 1047
2024
Q2 		$1.69M Buy
21,045
+2,542
+14% +$188K 0.01% 1060
2024
Q1 		$1.48M Hold
18,503
– – 0.01% 1090
2023
Q4 		$1.47M Hold
18,503
– – 0.01% 1103
2023
Q3 		$1.29M Buy
18,503
+1,282
+7% +$95.8K 0.01% 1103
2023
Q2 		$1.24M Buy
17,221
+321
+2% +$23.7K 0.01% 1146
2023
Q1 		$1.04M Hold
16,900
– – 0.01% 1208
2022
Q4 		$1.3M Buy
16,900
+558
+3% +$33.4K 0.01% 1083
2022
Q3 		$729K Sell
16,342
-1,006
-6% -$50.3K 0.01% 1370
2022
Q2 		$664K Hold
17,348
– – 0.01% 1474
2022
Q1 		$718K Buy
17,348
+6,439
+59% +$200K ﹤0.01% 1544
2021
Q4 		$412K Hold
10,909
– – ﹤0.01% 1610
2021
Q3 		$360K Hold
10,909
– – ﹤0.01% 1717
2021
Q2 		$736K Hold
10,909
– – 0.01% 1347
2021
Q1 		$618K Hold
10,909
– – 0.01% 1400
2020
Q4 		$889K Sell
10,909
-1,403
-11% -$105K 0.01% 1193
2020
Q3 		$877K Hold
12,312
– – 0.01% 1092
2020
Q2 		$1.01M Buy
12,312
+680
+6% +$52.3K 0.01% 1027
2020
Q1 		$684K Buy
11,632
+962
+9% +$78.4K 0.01% 1059
2019
Q4 		$1.1M Sell
10,670
-1,027
-9% -$41.5K 0.01% 1054
2019
Q3 		$237K Hold
11,697
– – ﹤0.01% 1850
2019
Q2 		$301K Buy
+11,697
New +$234K ﹤0.01% 1784

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MetLife Investment Management's AXSM Position: Q2 2026 in Review

MetLife Investment Management reduced its Axsome Therapeutics (AXSM) stake by 41% in Q2 2026, selling an estimated $13.7M and leaving 89,662 shares worth $21.9M. The position accounts for 0.1% of the portfolio, ranked #159.

MetLife Investment Management first reported a position in AXSM in Q2 2019 and has held it in 29 quarters since. The position peaked at $30.1M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • MetLife Investment Management held 89,662 shares of Axsome Therapeutics worth $21.9M as of Q2 2026.
  • MetLife Investment Management sold 62,983 Axsome Therapeutics shares in Q2 2026, an estimated $13.7M.
  • Axsome Therapeutics made up 0.1% of MetLife Investment Management's portfolio in Q2 2026, its #159 holding.
  • MetLife Investment Management first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • MetLife Investment Management's Axsome Therapeutics position peaked at $30.1M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.